의학신문_영문기사

Writer 최고관리자

Date 21-07-19 09:26

Read 94

2cc8a887506b344950eb9883db68745d_1627887310_5963.jpg
 


Heuron Stands at Forefront of Neurological Diseases Based on "Clinical AI"

 

Unveils World's First MRI-based Parkinson's Disease Diagnosis Support System "mPDia" and Alzheimer’s Brain Analysis System "Veuron-Brain-pAb"

 

 

Heuron, a representative company in medical AI solution (CEO Dong Hoon Shin, Myung Jin Shin), is unveiling world's first MRI-based Parkinson's disease diagnosis assistant software (mPDia) and a software for quantified analysis of Alzheimer's Brain (Veuron-Brain-pAb) at Korea's largest medical device exhibition "KIMES 2021."

 

Opening New Era for Early Diagnosis of Parkinson's Disease

 

- The world’s first Parkinson’s disease diagnosis : Heuron developed the most sophisticated AI-based PD diagnostic software for unmet needs in clinical circumstances.

- Proven technical skills and reliable data : Finished clinical study with 10 major university hospitals including Seoul Asan Medical Cener and Seoul St. Mary’s Hospital, and published 6 SCI papers. Securing significant know-how in the field and testing results confirms the high levels of accuracy, sensitivity, and specificity.

 

In July last year, the company has been acknowledged for the differentiation in diagnosis technology, becoming the third innovative medical device and NET(New Excellent Technology) designated by the KFDA(Korean Ministry of Food and Drug Safety) and Ministry of Health & Welfare.

 

Heuron’s mPDia is expected to reduce the time and cost of new drug development and increase clinical success rates. According to an industry insider, it can be used as a targeted screening technology to maximize the effectiveness of new drugs and will be a clear biomarker to determine the effectiveness of disease mitigation for the pharmaceutical company.

 

 

Korea's First to Receive U.S. FDA Approval for Alzheimer's Disease Analysis Software

 

- Quantitative analysis of β-amyloid protein by SUVR(Standardized Uptake Value Ratio) : It can be used in an objective solution on the clinical study fields, enabling a quantitative analysis of amyloid PET imaging, and thus delivering data on the brain location through the integration with MRI images.

 

Heuron's β-amyloid protein quantification analysis software received U.S. FDA approval, making it the first Korean medical AI company in the field of central nervous system (CNS) to get approval.

 

PET brain scans for Alzheimer’s disease by accumulation of β-amyloid which have been used until now utilizes analysis based on visual standards, and therefore, had to be reliant on the diagnostic accuracy of evaluators with high level of expertise.

 

 

Company introduction

 

Heuron is a healthcare start-up company founded in 2017 by a experienced neurologist, Dr. Dong Hoon Shin with faculty member of the Neurologists, Radiologists, and Medical engineers. As medical AI company led by a clinician, the company develops Parkinson's Disease, stroke, dementia and other CNS pipeline.

 

 

[Contact info]

www.iheuron.com / info@iheuron.com